Anti-aging Neuropeptides Under research

Dihexa

Also known as: PNI-0509

Dihexa is a small oligopeptide experimentally designed as a prodrug that easily crosses the blood-brain barrier. Developed at Washington State University, its primary purpose is to treat neurodegenerative conditions or brain trauma by forcing the creation of new brain synapses. It is considered one of the most potent nootropic (cognitive enhancing) agents known, with synapse-forming efficacy described as 10 million times stronger than natural BDNF.

Mechanism of action

Binds and activates HGF (Hepatocyte Growth Factor) signaling and its cellular receptor c-Met.
Efficiently crosses into the brain and triggers profound and rapid synaptogenesis (creation of synaptic connections) in the hippocampus and cerebral cortex.
Unlike externally administered BDNF (Brain-Derived Neurotrophic Factor), Dihexa is highly bioavailable and metabolically stable.

Uses & indications

Cognitive enhancement: Extreme increase in memory, retention, and learning.
Neurodegeneration: Experimental treatment to repair Alzheimer's and dementia damage, rebuilding lost neural networks.
Cranial trauma and TBI: Accelerated post-concussion brain rehabilitation.

Effects

Substantial improvement in verbal fluency, mental clarity, ease of learning, and short/long-term memory recovery. Users report a sustained cognitive "awakening."

Considerations & contraindications

Given that it strongly stimulates growth factor pathways (c-Met), there is a theoretical risk of favoring pre-existing tumor growth. It should not be used if there is a history of cancer.
It is very potent and can cause over-excitation or tension headaches.

Regulatory approval

Licensed for neuropharmacological research. Not FDA approved.

Dosage

Oral/transdermal doses are typically 10mg to 20mg once or twice a week, given its potent cumulative effect.

Storage

Powder is stable at cool room temperature. Avoid extreme heat.

Technical data

Regulatory status Under research

Molecular weight 506.6 Da

Half-life Prolongada (Días en tejido cerebral)

Administration routes Transdérmica (Crema), Oral, o Subcutánea